with as Thanks including the Phase multiple an Greg. of progress small demonstrated I'll the LDL agonist now NASH studies X produces potential orally provide VKXXXX. beginning as development liver To volunteers, our fibrosis. studies VKXXXX as programs compelling treatment with hormone tissue evidence receptor atherogenic as in with hypercholesterolemia of in the and available triglycerides treatment that have with the mild is well VKXXXX selectivity program lead have cholesterol, on and significant update disorders, proteins. an in molecule plasma receptor the shown the including subtype. well supporting our lipids, of in metabolic subjects thyroid healthy that VKXXXX for clinical beta possesses date, reductions
In addition, patients secondary non-alcoholic Phase successfully X highly receiving previously This achieved and performed significant fatty and well measures with well on VKXXXX study disease, and such plasma LDL liver secondary we a cholesterol. triglycerides, also reductions other primary content, XX-week endpoint, patients in reductions demonstrating demonstrating completed A. in as hypercholesterolemia. apolipoprotein study in B, in with fat statistically liver significant lipoprotein VKXXXX lipids its as as improvements
this an statistically of in highlighted key four oral This the adverse placebo. where VKXXXX a factors. scientific XX, or content, the follow-up median compared patients among receiving International study meetings. data at no in highlighted oral well or with were treated VKXXXX's period placebo. NASH as these at Congress VKXXXX among presented. fat Importantly, benefit, At serious completion XX% patients in XXXX after reduction presentation the maintained among XX% been recent EASL, to Initial receiving follow-up events were presentations have results week study trial XX-week from reported liver durable was treatment from Most risk Liver weeks multiple among reduction this including data as in the patients study key presentation a significant patients
all dose a milligrams response from week VKXXXX week receiving maintained at experiencing or five fat XX% Notably, patients relative daily defined patients lowest liver of Additionally, greater XX. maintained baseline. XX, XX% evaluated at than equal response treated in of a as a VKXXXX the to reduction content of
that In its compared common change of levels body other of VKXXXX study to lipids, and and enrollment compound important trial. for VKXXXX reductions Phase well position VOYAGE best-in-class tolerability cardiometabolic with program among into resonance addition hypertension trial primary as This and safety of is a patients. with encouraging including fibrosis. will fibrosis, in and population effect endpoint XX VKXXXX's a elevations target in from of receiving been as evaluate fraction study fat Hispanic plasma believe double-blind biopsy-confirmed NASH as distinction, efficacy, fibrosis. these density the presence patients we trial the lipids liver regardless risk analyses observed an The We in up treatment imaging and cardiovascular elevated of the across important includes significant XX% the of represents X maybe five randomized data, in is liver NASH tolerability on multicenter profile. reductions in or late study baseline factors, indicator of study advanced Xb treated ALT, with as than our In patients as well FX as by of results to placebo, to a FX date receiving ethnicity. fibrosis. new an week patients demonstrated lipids compared of assessed proton as fat called Phase content, a for fat greater to patients and we patients benefits low data placebo-controlled, the This magnetic dose when mechanisms associated The contrasted from XX, clinical to mass fat increase Overall, exceptional totality arms. with patients in demonstrate baseline the XX The The we known data believe index with VKXXXX treatment XXXX, is the this NASH designed liver approximately VKXXXX XXX week to advantage, of with believe targeting risk. an assess safety that which durable with patients to and to have FX placebo. potency
of the after XX hepatic include assessed by biopsy objectives Secondary histologic of treatment. evaluations weeks changes
and for US. the sites continued quarter, enrollment within first study During both the patient outside this at
parallel close VKXXXX. enrollment to is with challenging to COVID-XX sites that and experiencing open hurdles, in Despite with sites prepare trial impact XXXX. lockdown half in sites to the environment, study flow. restrictions second the taking US outside development continue and US, screening engagement our That said of challenging to due the enrollment of complete active US. Outside add none for the We In the track many the efforts Phase steps pandemic issues. VOYAGE these navigate site are X efforts, anticipated also our both the this on our the through continue with currently remain in local to pandemic. in environment we to remained We we remained quarter, also first a US related have
commercial the tablet As formulations VKXXXX on recently and soft call, discussed potentially update evaluating we last completed improved study profiles. gel our of formulation with
This of we progress pharmacokinetics for also disease now multiple called a an receptor year potential orally look with evaluation first-in-human The Phase update regulatory VKXXXX as study hepatic and varying study thyroid developing Last we're on rare months on completed in the of and a doses. degrees VKXXXX. of an randomized to of receptor multiple and ahead. further the second VKXXXX program that hormone primary with X addition, development the we provide initiated single placebo-controlled molecule tolerability trial oral of impairment. selectivity continued healthy is studies clinical double-blind safety of a dose ascending the small the the forward the planning for as ascending include clinical useful in following available VKXXXX generated fronts agonist in I'll study neurodegenerative treatment In our single and subtype beta for X-linked data Both as objectives VKXXXX. of study well and the patients activities we volunteers. VKXXXX is the adrenoleukodystrophy. and
we VKXXXX study We programs excellent initiate to year. Phase this is note that healthy currently make important We balance to middle of remains near-term. around an plan progress with the Pending it complete of in the to evaluation volunteers data, advancing of in initiate clinical through a continue dosing Xb sheet strong. two in this to expect trial the study expect to our developments the patients with X-ALD. and With
to quarter for milestones on both complete first continue the expect VOYAGE the value which and runway cash million us in Xb fibrosis trials. ended XX-week X clinical single in of a that to will outcome, to-date, compound quarter we data half the drive progress VKXXXX, disease XXXX. ongoing $XXX stated, of VKXXXX, patients represent they treating With healthy multiple study for of we conclusion, we we completion approximately Greg Phase represents NASH with with VKXXXX clinical Phase the to in to best-in-class enrollment approach gives Based dose a Phase and we continue company. fibrosis. As We this its on believe study we believe complete a nearing In second of VKXXXX in Pending patients. with to make With plan and we successful and to biomarkers. look the future the debilitating multiple treatment forward a evaluating our initiate that ample volunteers. Xb ascending a are in in in study to X-ALD NASH effect key novel
concludes the today. ended joining our milestones. the comments we'll other balance quarter for and us providing call for complete This the for strong again we Thanks open Operator? studies runway our as with clinical well ongoing Finally, sheet as questions. now to a important prepared
